NCT02719197View on ClinicalTrials.gov

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 19, 2016

Primary Completion Date

December 1, 2016

Study Completion Date

December 1, 2016

Conditions
Healthy Subjects
Interventions
DRUG

AC-083

Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg

DRUG

Placebo

Placebo capsules matching AC-083 capsules

Trial Locations (1)

14050

Investigator Site, Berlin

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT02719197 - First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders | Biotech Hunter | Biotech Hunter